Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & Beyond

With continued advancements in screening platforms and proteomics, the covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology, immunology and CNS. We are witnessing this industry make great strides in utilizing novel covalent modalities and elucidating novel warheads to target amino acids beyond cysteine. However, developing covalent drugs remains no easy feat, as knowledge gaps persist in balancing reactivity and selectivity, de-risking the ligandability of alternative residues, and tackling PKPD disconnects and efficiency bottlenecks to successfully develop potent covalent drugs for unmet clinical need.

The 2nd Covalent Drug Discovery & Development Summit returns as the leading networking and learning opportunity for the covalent community, spanning every aspect of covalency from discovery to translation and clinical development, equipping 100+ proteomics, chemical biology, biochemistry and pharmacology leaders with the means to expand the druggable proteome.